Sign in Subscribe
Pharmaceutical industry

Johnson & Johnson's COVID-19 Vaccine Wins EU Approval Amid Slow Immunization Campaign

Strategic Insights

— 2 min read

The European Union's (EU) drugs regulator has recommended approval for Johnson & Johnson's single-dose COVID-19 vaccine, paving the way for its conditional marketing authorization. This approval marks the fourth vaccine cleared in the region, following AstraZeneca, Pfizer-BioNTech, and Moderna. The EU has purchased 200 million doses of the vaccine, with an option for an additional 200 million. The vaccine's simplicity in logistics and refrigeration storage could help accelerate the bloc's immunization effort.

Key Takeaways:

  • The European Commission granted a conditional marketing authorization for Johnson & Johnson's COVID-19 vaccine after the EU's drugs regulator recommended approval for all adults.
  • The vaccine will be the fourth to be cleared in the region, following AstraZeneca, Pfizer-BioNTech, and Moderna.
  • The EU has purchased 200 million doses of the vaccine, with an option for an additional 200 million.
  • The vaccine's simplicity in logistics and refrigeration storage makes it easier to administer and store compared to Pfizer and Moderna vaccines.
  • The J&J vaccine was found to be 67% effective against symptomatic COVID-19 in trials conducted in areas with high prevalence of new variants.
  • In the US arm of the studies, the vaccine prevented 72% of infections.
  • Thomas Mertens, the head of Germany's vaccine commission, praised the vaccine trials and presented data, saying it is "the best data we have seen."
  • The protection offered by the J&J vaccine is below what Pfizer-BioNTech and Moderna offer, but its ease of use makes up for that.
  • Side effects of the vaccine include headaches, tiredness, and pain at the injection site.
  • Johnson & Johnson has received approximately $1.5 billion in funding for the vaccine from the United States through Operation Warp Speed.
  • The company is also conducting a two-dose trial of its shot.

Statistics:

  • The EU has purchased 200 million doses of the Johnson & Johnson vaccine, with an option for an additional 200 million.
  • The vaccine has been found to be 67% effective against symptomatic COVID-19 in trials.
  • In the US arm of the studies, the vaccine prevented 72% of infections.
  • The J&J vaccine's efficacy is below what Pfizer-BioNTech and Moderna offer ( 90% and 94% respectively)
  • The vaccine has been approved by the US FDA and is being rolled out through Operation Warp Speed.
  • The company has received $1.5 billion in funding from the US government.

Sources:

  • Bloomberg, "Johnson & Johnson’s Vaccine Wins EU Approval, Adding to Europe’s Immunization Arsenal"
  • European Commission, "Conditional Marketing Authorization for COVID-19 Vaccine"
  • Johnson & Johnson, "Johnson & Johnson’s Janssen COVID-19 Vaccine Receives Conditional Marketing Authorization from the European Commission"
  • US FDA, "Emergency Use Authorization for Johnson & Johnson's Ad26.COV2.S COVID-19 Vaccine"

Read more